



Fast-growing global biopharmaceuticals company & leading provider of affordable medicines



Diversified portfolio of 290+ products across Specialty, Biosimilars, Injectables and Retail Generics



Expansive R&D, manufacturing and commercial capabilities at scale with vertical integration




Robust R&D engine generating 20-30 new retail and injectables product launches consistently per year; focused on high-value, complex products



Accelerated revenue and profit growth outlook with higher cash flow generation and continued deleveraging

Diversified portfolio delivering sustainable growth...



Retail Generics

#4 U.S. Generics portfolio, shift to complex dosage forms



Injectables

Expanding portfolio of 40+ institutional products with new differentiated 505(b)(2) injectables for hospitals



Biosimilars

Drive uptake of 3 commercial biosimilars and expand portfolio with next 5 biosimilars



AvKARE

Expanding presence across channels & dosage forms



Specialty

Branded therapies focused on Neurology and Endocrinology - highlighted by CREXTONT® for PD




International

Market expansion in India, Europe & rest of world

Adjusted EBITDA growth

\$ in millions



Financials

\$ 3.0 - 3.1B

+7 to 11% Growth
2025 Net Revenue guidance

\$675 - 685M

+8 to 9% Growth 2025
Adj. EBITDA guidance

3.7X

Net leverage as of September 30, 2025

NASDAQ

AMRX